Device Glaucoma

Istent Trabecular Micro-Bypass System Model Is3

Payments companies reported to CMS as associated with Istent Trabecular Micro-Bypass System Model Is3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$300Kassociated payments (2023-2025)
1,624clinicians with associated payments
1company reporting

By year

2024 $300K

Payments reported as associated with Istent Trabecular Micro-Bypass System Model Is3, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Ophthalmology $213K
Optometrist $27K
Glaucoma Specialist $14K
Neuro-Ophthalmology $11K
Retina Specialist $9,140
Cornea and External Diseases Specialist $8,589

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Istent Trabecular Micro-Bypass System Model Is3

These are the largest totals companies reported as associated with Istent Trabecular Micro-Bypass System Model Is3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Iqbal Ahmed Salt Lake City, UT Ophthalmology $48,735.12
Syed Khizer Khaderi Stanford, CA Neuro-Ophthalmology $10,747.50
Inder Singh Racine, WI Ophthalmology $7,342.42
Mitchell Shultz Northridge, CA Ophthalmology $3,317.89
Manjool Shah Ann Arbor, MI Ophthalmology $3,087.97
Jonathan Schulhof Brooklyn, NY Glaucoma Specialist $2,666.12
Brian Shafer Plymouth Meeting, PA Cornea and External Diseases Specialist $2,609.02
Tad Schoedel Roanoke, VA Ophthalmology $2,539.26
Anna Mackin Roanoke, VA Retina Specialist $2,500.00
Will Griffeth Salem, VA Ophthalmology $2,500.00

Prescribed Istent Trabecular Micro-Bypass System Model Is3?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.